The randomized, open-label, phase 3 study KEYNOTE-48 demonstrated the superiority of pembrolizumab monotherapy in PD-L1-positive patients and was not inferior compared to the standard first-line EXTREME (fluorouracil/platinum/cetuximab) regimen for R/M HNSCC. Here, CD274 is linked to head and neck squamous cell carcinoma.